GuruFundPicks
Consensus Picks DIY Tools, Top 20 Small-cap Newsletter, Trade Alert Service (Auto)

Cerus - An Attractive Long-Term Buy Based On Positive Pipeline Developments

Cerus's pathogen inactivation technology is positioned to become the global standard of care for safe blood transfusions. Shares can triple over the next 12-18 months.

Concord, CA-based Cerus Corp. (NASDAQ:CERS) develops and markets the INTERCEPT Blood System designed to enhance blood safety by inactivating blood-borne pathogens in donated blood components intended for transfusion. It holds worldwide rights for the INTERCEPT Blood System for all three blood components, namely platelets, plasma and Red Blood Cells (RBCs). It received the CE marks for platelets and plasma, in 2007 and 2006 respectively, and currently markets them in Europe, the Middle East and the Commonwealth of Independent States (CIS) via a direct sales force and distributors. Its pathogen inactivation technology is inherently...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details